Summit Therapeutics (SMMT) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to 0.73.
- Summit Therapeutics' Equity Ratio fell 1564.92% to 0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73, marking a year-over-year decrease of 1564.92%. This contributed to the annual value of 0.89 for FY2024, which is 13314.75% up from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Equity Ratio is 0.73, which was down 1564.92% from 0.8 recorded in Q2 2025.
- Summit Therapeutics' Equity Ratio's 5-year high stood at 0.9 during Q1 2025, with a 5-year trough of 0.19 in Q4 2022.
- Its 5-year average for Equity Ratio is 0.62, with a median of 0.57 in 2024.
- As far as peak fluctuations go, Summit Therapeutics' Equity Ratio plummeted by 7404.07% in 2022, and later skyrocketed by 25872.37% in 2025.
- Summit Therapeutics' Equity Ratio (Quarter) stood at 0.73 in 2021, then crashed by 74.04% to 0.19 in 2022, then skyrocketed by 100.75% to 0.38 in 2023, then soared by 133.15% to 0.89 in 2024, then decreased by 17.7% to 0.73 in 2025.
- Its Equity Ratio stands at 0.73 for Q3 2025, versus 0.8 for Q2 2025 and 0.9 for Q1 2025.